Diabetic Nephropathy Market, By Drug Class (Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Diuretics, Calcium Channel Blockers, and Others (e.g., GLP 1 Receptor Agonists, DPP 4 Inhibitors, Endothelin A Receptor Antagonists, Fibrosis/Inflammation Modulators)), By Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), By Route of Administration (Oral, Parenteral (injectables/infusions), and Other routes (e.g., transdermal, novel delivery)), By Gender (Male and Female), By Age Group (Pediatric and Adult), By Disease Stage (Early Stage, Moderate Stage, and End-Stage Renal Disease (ESRD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals and Clinics, Specialty Nephrology Centers, Home Care/Ambulatory Care, and Other settings (dialysis centers, renal transplant units)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)